On February 6, 2018, UACT and 43 other organizations sent a letter to leaders in Congress, urging them to increase patients access to generic drugs by passing the CREATES Act. When the FDA registers a brand name drug, it sometimes requires the manufacturer to submit a risk management strategy (called REMS), containing a plan for how the drug will be managed in order to ensure that the benefits to patients outweigh the potential risks of side effects or adverse outcomes. These protocols can include restrictions on how and to whom the drugs can be distributed, for example saying that a drug can only be dispensedRead More →

UACT applauds the Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number 1014, passed by a 96-0 vote with one abstention, and includes the signatures of representatives across the entire political spectrum 1. In Chile, the private market price of sofosbuvir at the time of the compulsory licensing request was approximately $36,000 USD per patient. This price is well in excess of Chile’s GNI per capita of $14,100 USD 2. The Ministry of Health currently pays $7,000 USD for a three-month supplyRead More →

On December 12, 2017, the Medicines Patent Pool (MPP), a United Nations-backed public health organisation with the mission to increase access to HIV, hepatitis C and tuberculosis treatments in low- and middle-income countries, made a welcome announcement for cancer patients: the expansion of MedsPaL. MedsPaL is a database created to provide information on the intellectual property status of priority medicines in developing countries, to patented treatments on the World Health Organization (WHO)’s Model List of Essential Medicines (EML), and its expansion is certainly a step in the right direction.   UACT was encouraged to see that data on patents for certain medicines to treat chronicRead More →

On December 8, 2017, UACT submitted a letter to the US, Canadian, and Mexican representatives of the NAFTA re-negotiations. Please find below the full text of the letter. A PDF version is available here. Union for Affordable Cancer Treatment 1621 Connecticut Avenue NW Suite 500 Washington, DC 20009 Tel.: 202.332.2670 www.uact.org December 8, 2017 Dear NAFTA Delegates, The Union for Affordable Cancer Treatment (UACT), created in 2014, is a union of people affected by cancer, their family members and friends, people who take care of people with cancer, health care professionals and cancer researchers committed to increasing access to effective cancer treatment and care. WeRead More →

On November 17, 2017, UACT submitted written comments the US Food and Drug Administration’s request for comments concerning, “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.” The call for comments followed a public meeting hosted by the FDA in July 2017. The comments submitted by UACT call for the FDA to support three measures that would help increase access to cancer treatments and other medical technologies.  These measures include compulsory licensing as leverage for the proposed Medicare negotiation powers, the FDA to require greater transparency of R&D costs as a condition of marketing approval, and support for feasibility studies to explore businessRead More →